The recent successful development of monoclonal antibodies that target key components of biological pathways has expanded the armamentarium of treatment options for patients with colorectal cancer (CRC). In particular, the epidermal growth factor receptor (EGFR), a tyrosine kinase growth factor receptor involved in CRC development and progression, is exploited by the newest monoclonal antibody that is available for use in CRC patients. Cetuximab, the first chimeric monoclonal antibody, which has been generated against the EGFR, is currently registered in USA, Europe and worldwide, in combination with irinotecan in the treatment of metastatic CRC patients who have progressed on irinotecan containing chemotherapy. Cetuximab is well tolerated and does not exacerbate the toxicity of concomitant chemotherapy. Furthermore, a series of phase III clinical trials are currently evaluating the combination of cetuximab with standard chemotherapy regimens in the first-line treatment chemotherapy-naı¨ve patients with metastatic CRC.
Introduction
Colorectal cancer (CRC) is one of the most common malignancies and is the second leading cause of cancerrelated deaths in Europe and in North America. Surgery is the only curative treatment for CRC. However, approximately 25-50% of patients may have a recurrent disease at distant sites following radical surgery. During the past four decades, the antimetabolite 5-Fluorouracil (5-FU) has been the cornerstone of chemotherapy for advanced disease. More recently, new chemotherapeutic drugs with different mechanisms of action such as irinotecan and oxaliplatin have been demonstrated to be active in combination with 5-FU. Therefore, 5FU-irinotecan or 5FU-oxaliplatin combinations have become the standard first-line regimens in metastatic CRC (Braun et al., 2004) . Although there is clear evidence that chemotherapy in the first-line setting improves time to disease progression (TTP), overall survival (OS) and quality of life (QL), overall treatment results remain unsatisfactory.
The role of epidermal growth factor receptor (EGFR)-driven intracellular signaling in colorectal carcinogenesis has been well established (Arteaga, 2001) . The EGFR, also called HER-1, is a 170 kDa transmembrane glycoprotein that consists of an extracellular domain, a hydrophobic transmembrane domain, and an intracellular region containing the tyrosine kinase domain. The EGFR exists as inactive monomers, which dimerize following ligand activation (Salomon et al., 1995; Salomon and Gullick, 2001 ). This causes homodimerization or heterodimerization between EGFR and one of the three other members of the EGFR family. Following ligand binding, the tyrosine kinase intracellular domain of the receptor is activated, with autophosphorylation of the intracellular domain, which initiates a cascade of intracellular events that ultimately regulates cell proliferation, migration, invasion, adhesion, differentiation and survival (Salomon et al., 1995; Olayioye et al., 2001; Salomon and Gullick, 2001) . Activation of the EGFR autocrine growth pathway is a common mechanism for autonomous, dysregulated cancer cell growth in the most common types of human epithelial cancers. This can be due to several mechanisms, such as increased expression of the EGFR, increased concentration of ligands, decreased receptor turnover, the presence of aberrant receptors due to EGFR gene alterations. More recently, point mutation or small in-frame deletions in specific EGFR gene exons such as those codifying for the tyrosine kinase domain (mostly exons 19 and 21) have been described in a subset of non small-cell lung cancer (NSCLC) (Lynch et al., 2004) . EGFR overexpression has been generally associated with advanced disease and poor prognosis and with the development of resistance to anticancer treatments (Wosikowski et al., 1997; Akimoto et al., 1999; McClelland et al., 2001; Yarden and Sliwkowski, 2001; Galizia et al., 2006) . EGFR is overexpressed in approximately 70-80% of metastatic CRC.
Two therapeutic strategies have been successfully developed in the past decade to target the EGFR pathway in cancer: monoclonal antibodies (MAbs) and small molecule inhibitors of the EGFR tyrosine kinase enzymatic activity. MAbs are generally raised against the extracellular domain of the EGFR to block ligand binding and receptor activation (Mendelsohn, 2000 (Mendelsohn, , 2001 Ciardiello and Tortora, 2001; Grunwald and Hidalgo, 2003; Mendelsohn and Baselga, 2003) . The blockade of EGFR signaling in cancer cells causes not only inhibition of cell proliferation but also other effects, including antiangiogenetic mechanisms (Mendelsohn, 2001 ). Cetuximab (Erbitux) is a MAb that binds selectively to the EGFR and competitively inhibits endogenous ligand binding. By preventing the binding of EGF and TGFa, cetuximab inhibits EGFR activation and the associated downstream intracellular signaling. In addition to preventing ligand binding, cetuximab stimulates EGFR internalization and degradation, leading to receptor downregulation (Mendelsohn and Baselga, 2003) . Cetuximab has demonstrated antitumor activity against a variety of cancer cell lines in preclinical studies (Kim et al., 2001; Ciardiello and Tortora, 2002; Herbst and Shin, 2002) . Based on the promising preclinical results, further research with cetuximab has focused on three tumor types: NSCLC, squamous cell cancer of the head and neck and CRC (Kim et al., 2001; Ciardiello and Tortora, 2002; Herbst and Shin, 2002) . This review will focus on the role of cetuximab in the treatment of patients with advanced CRC.
Molecular properties and clinical pharmacology
Cetuximab is a human-mouse chimeric anti-EGFR that contain the human IgG 1 constant region. It is a 152-kDa molecule, composed of four polypeptide chains: two identical heavy (lambda) chains, each consisting of 449 amino acids and two identical light (kappa) chains, each consisting of 214 amino acids. The four chains are held together by a combination of covalent and non-covalent bonds. The light chain and heavy chain subunits contains one and two consensus sequences for N-linked glycosylation, respectively. The N-terminal residue of the heavy chain is cyclized as pyroglutamic acid. There are 32 cysteine residues and, accordingly, 16 potential disulfide bonds per molecule (Humblet, 2004) . Cetuximab binds to the EGFR with a 10-fold greater affinity than mouse MAb 225 from which it is derived and blocks EGF-induced autophosphorylation of the EGFR in cancer cells (Mendelsohn and Baselga, 2003) . Cetuximab also induces internalization of the EGFR (Mendelsohn, 2000 (Mendelsohn, , 2001 . In this respect, EGFR downregulation may contribute to the inhibitory effects of this antibody. Cetuximab treatment blocks cell-cycle progression by inducing a G1 arrest through an increase in the protein levels of the p27 kip1 inhibitor of cyclindependent kinases (Peng et al., 1996; Wu et al., 1996; Galizia et al., 2006) . Cetuximab also induces cancer cell apoptosis, by altering the ratio of Bax to Bcl-2 expression, and by increasing expression of apoptotic caspases. Cetuximab inhibits the growth of human epidermoid, prostate, colon and renal cell carcinoma xenografts in vivo (Mendelsohn and Baselga, 2003) . Studies using human cancer xenografts in nude mice have demonstrated that cetuximab inhibits tumorinduced angiogenesis (Perrotte et al., 1999; Bruns et al., 2000; Ciardiello et al., 2000; Inoue et al., 2000; Ciardiello and Tortora, 2002) . This is probably due to reduced tumor production of angiogenic factors, including TGF-a, vascular endothelial growth factor (VEGF), interleukin-8 and basic fibroblast growth factor. A supraadditive and/or synergistic potentiation of in vitro growth inhibition has been observed in human cancer cell l ines treated with cetuximab in combination with different cytotoxic drugs including doxorubicin, cisplatin, paclitaxel, gemcitabine, irinotecan, oxaliplatin and topotecan (Ciardiello et al., 1999; Bruns et al., 2000; Inoue et al., 2000; Mendelsohn, 2001; Humblet, 2004) . In nude mice bearing DLD-1 and HT-29 CRC xenografts, cetuximab in association with irinotecan or irinotecan/5-FU/folinic acid (FA) led to a significant synergistic antitumor activity. Significantly, the growth of CRC xenografts refractory to single agent irinotecan was inhibited by the combination of cetuximab and irinotecan, suggesting that adding cetuximab to irinotecan may help to overcome irinotecan resistance. These preclinical indications suggest a role for cetuximab in irinotecan-refractory CRC patients (Prewett et al., 2002) . Several preclinical studies have also shown an enhancement of tumor response to radiotherapy by combined treatment with cetuximab in human epidermoid, head and neck, and colon cancer xenografts (Huang et al., 1999; Saleh et al., 1999; Bianco et al., 2000; Huang and Harari, 2000; Milas et al., 2000) . Among the potential mechanisms that contribute to the increased radiation sensitivity by treatment with cetuximab, it has been suggested an accumulation of cancer cells in the more radiosensitive cell-cycle phases (G 1 , G 2 -M), a blockade of radiation-induced DNA repair mechanisms, a reduction of VEGF production by cancer cells with inhibition of tumor angiogenesis (Huang and Harari, 2000) .
In patients with metastatic CRC treated with cetuximab 400 mg/m 2 as initial dose followed by 250 mg/m 2 weekly in association with irinotecan either alone or with FA and 5-FU, mean peak serum concentrations of 153-202 mg/ml and the area under the plasma concentration-time curve values of 21 520-17 337 mg/h/ml were recorded between weeks 1 and 4 of treatment (Debaldo et al., 2003; Folprecht et al., 2005) . Cetuximab has a mean volume of distribution of 45.2-61.9 ml/kg, approximately equivalent to plasma volume, at intravenous doses of 20-100 mg/m 2 given at weekly intervals for 4-12 weeks, as demonstrated in two phase I studies (Folprecht et al., 2005) . The major route of cetuximab clearance is through binding of the antibody to EGFR in many tissues, including the liver and the skin, which subsequently internalizes the antibody-receptor complex and removes it from circulation (Baselga et al., 2000; Robert et al., 2001; Folprecht et al., 2005) . Cetuximab clearance decreases with increasing dose, indicating saturation of the metabolic pathway and nonlinear pharmacokinetics at lower doses. It has a mean serum elimination half-life of 79-129 h at a dosage of 400 mg/m 2 followed by 250 mg/m 2 weekly, after 1-4 weeks of treatment. Moreover, several studies suggest that continuous saturation of the EGFR is achieved and maintained in the majority of patients with an initial dose of 400-500 mg/m 2 , followed by 200-300 mg/m 2 weekly (Debaldo et al., 2003; Folprecht et al., 2005) .
Clinical activity in irinotecan-refractory metastatic colorectal cancer
Several studies have shown that cetuximab is effective in patients with metastatic CRC whose disease has progressed on irinotecan-based chemotherapy administered as their last regimen before study entry (Table 1) . The first report of activity was derived from a phase II multicentre trial, in which 121 patients refractory to irinotecan-based chemotherapy expressing EGFR, received cetuximab in combination with irinotecan. A 22.5% major objective response rate (RR) for irinotecan-refractory patients was obtained with a median duration of response of 6 months (Saltz et al., 2001) . The encouraging results seen in this trial led to initiation of a multicenter phase II study to evaluate the activity of single-agent cetuximab in irinotecan-refractory CRC. In that trial five out of 57 patients (9%) obtained partial responses (PR) confirmed by an independent response assessment committee (Saltz et al., 2004) . The most complete clinical data for the use of cetuximab in this setting have been obtained with a large, multicenter European randomized phase II clinical trial, named the BOND-1 (Bowel Oncology Cetuximab Antibody) study, which compared treatment with cetuximab monotherapy (111 patients) or with cetuximab in combination with irinotecan (218 patients) in advanced CRC patients with EGFR-positive cancer who have failed on an irinotecan-containing regimen as last treatment (Cunningham et al., 2004) . In this heavily pretreated patient population, 261/329 (79.3%) patients received two or more types of chemotherapy before study entry.
Moreover, 206/329 (62.6%) patients were pretreated also with an oxaliplatin-containing regimen. Partial responses were obtained in 22.9% patients treated with irinotecan plus cetuximab as compared to 10.8% patients treated with cetuximab alone (P ¼ 0.007). Similarly, a significantly better disease control (partial responses plus disease stabilization) was observed in the combination arm as compared to cetuximab monotherapy (55.5 vs 32.4%, Po0.001) (Cunningham et al., 2004) . The difference in terms of OS was not significant (median OS; 6.9 vs 8.6 months), but it must be noted that 56 patients who progressed on cetuximab monotherapy were switched to the cetuximab plus irinotecan combination arm. Furthermore, a significant improvement in TTP was observed in patients treated with cetuximab plus irinotecan (1.5 months vs 4.1 months; Po0.001). Subgroups analyses revealed that response to treatment was independent from the number of previous lines of chemotherapy. Probability of achieving a response was not correlated to the level of EGFR expression in the tumor. However, the presence and the intensity of skin toxicity were associated with clinical efficacy. In patients with 'acne-like' skin reactions after cetuximab treatment, the response rates were higher than those in patients without skin reactions (25.8 vs 6.3% in the cetuximab plus irinotecan combination arm,
Taken together, these data are particularly relevant for the clinical management of advanced CRC. In fact, the most active chemotherapy combinations, including fluoropyrimidine, irinotecan, oxaliplatin and bevacizumab, a humanized monoclonal antibody against human VEGF, obtain median survivals of 18-21 months in these patients. However, after failure of these drugs combinations, there are no effective treatment options. Therefore, cetuximab as monotherapy or in combination with irinotecan offers a promising new treatment option for this set of patients.
Cetuximab treatment is well-tolerated, either as monotherapy or in combination with chemotherapy; in particular, it is not associated with typical chemotherapy-induced side effects, such as myelosuppression, mucositis, nausea-vomiting and hair loss. In the combination studies with irinotecan and cetuximab, grade 3/4 toxicities according to WHO criteria were recorded in 72% of patients treated with cetuximab and irinotecan and 53% receiving cetuximab alone. Main grade 3/4 adverse events occurring in patients receiving cetuximab as monotherapy were acne-like rash (10%), asthenia (11%), dyspnea (10%) and abdominal pain Abbreviations: N/A, not available; OS, overall survival; RR, response rate; TTP, time to treatment progression.
Cetuximab in the treatment of colorectal cancer G Galizia et al (7%). The most common grade 3/4 toxicity reported in patients receiving cetuximab plus irinotecan were diarrhea (22%), leukopenia (17%), asthenia (14%), acne-like rash (12%) and abdominal pain (6%). Overall, 15% of patients receiving cetuximab and irinotecan discontinued therapy due to side effects compared with 12% receiving cetuximab alone. There were no deaths considered to be related to cetuximab treatment (Saltz et al., 2001 (Saltz et al., , 2004 Cunningham et al., 2004) . Acneiform skin rash is generally the most common adverse effect associated with cetuximab treatment, with a >60% incidence reported in the majority of the clinical trials. Nearly all skin reactions were seen within the first 5 weeks of therapy. The rash was predominantly on the face and upper trunk, and was reversible within 30 days of stopping cetuximab treatment. This adverse effect is thought to be due to cetuximab interference with the physiological role of EGF in the epidermis Busam et al., 2001; Holliwood, 2002) .
Based on these results, cetuximab is currently licensed in several countries worldwide. The first approval was granted in December 2003 in Switzerland for the use in combination with irinotecan in the treatment of EGFRexpressing metastatic CRC progressing after irinotecanbased chemotherapy. It has also received approval in February 2004 from the Food and Drug Administration (FDA) in USA for the treatment of patients with EGFR-expressing metastatic CRC either in combination with irinotecan in patients resistant to irinotecanbased chemotherapy or as monotherapy in patients intolerant to irinotecan-based chemotherapy. Finally, it received approval from the European Agency for the Evaluation of Medicinal Products (EMEA) for the 25 countries of the European Union in June 2004 for its use in combination with irinotecan in the treatment of EGFR-expressing metastatic CRC progressing after irinotecan-based chemotherapy.
As reported above for BOND study, there seems to be a correlation between the severity of cetuximab-induced skin reaction and the response rate and survival time following cetuximab therapy. An analysis of four phase II studies in different tumors, showed that patients who developed the acneiform rash survived longer than those who did not develop it, suggesting that skin rash may be a relevant surrogate of cetuximab clinical efficacy (Saltz et al., 2003) . To explore this hypothesis, a randomized phase I/II study of cetuximab plus irinotecan is currently ongoing to investigate the safety and efficacy of a dose escalation of cetuximab compared with the standard cetuximab dose in patients with irinotecanresistant, EGFR-expressing metastatic CRC.
Addressing the role of second-line cetuximab in irinotecan naı¨ve disease, a phase III EPIC trial is comparing cetuximab plus irinotecan with irinotecan alone as a second-line chemotherapy for patients with EGFR-positive metastatic CRC progressing on an oxaliplatin/5-FU based regimen. Target accrual is 1300 patients and OS is the primary end point. Preliminary data on the safety have been presented, showing that the use of cetuximab with irinotecan appear to be feasible with toxicity profile similar to that of previous study (Abubakr et al., 2006) . A palliative National Cancer Institute of Canada Clinical Trial Group phase III clinical trial is comparing cetuximab plus best supportive care with best supportive care alone in patients for whom best supportive care is the only remaining treatment option. A total of 500 patients are expected for accrual, with the treatment to continue in the absence of disease progression or unacceptable toxicity.
Cetuximab as up-front therapy
Cetuximab has established activity in the salvage setting, however, its role in the first-line therapy remains investigation at this time. Preliminary data from phase II trials have reported encouraging results (Table 2 ). In a phase II North American study, 29 patients received cetuximab in combination with bolus 5-FU/FA and irinotecan, with a RR of 44% (Rosemberg et al., 2002) . As expected, diarrhea and neutropenia were most common adverse events, and grade 3 rash occurred in 19% of patients. In a phase I/II European study, cetuximab combined with irinotecan plus infusional 5-FU/FA (modified AIO regimen) was associated with a RR of 67% with a disease control rate of 96% (Folprecht et al., 2005) . Additionally, a phase I/II trial of FOLFIRI plus cetuximab in first-line therapy with two dose levels of 5-FU resulted in encouraging preliminary data. Of 40 valuable patients, a 43% PR rate was reported, with five initially unrespectable patients undergoing an RO resection and with minimal grade 3-4 toxicities (Rosemberg et al., 2002) . A phase II trial of FOLFOX4 plus cetuximab for previously untreated metastatic CRC patients reported preliminary encouraging activity (Badarinath and Jennis, 2004 Cetuximab in the treatment of colorectal cancer G Galizia et al were reported for a RR of 81%, without a higher incidence of grade 3-4 diarrhea or neutropenia compared with historical controls. A phase I/II trial of cetuximab plus 5-FU/LV (two dose cohorts) and weekly oxaliplatin (50 mg/m 2 ) (FUFOX) in first-line treatment has reported preliminary data from 38 of 49 enrolled patients (Hohler, 2004) . One CR and 20 PRs were reported with an overall RR of 55%. The 41 patients valuable at dose level 2 reported significant grade 3-4 diarrhea (24%) and skin reactions (17%), and preliminarily 7% grade 3-4 neurotoxicity. Based on these results, several randomized, phase III clinical trials of cetuximab in combination with different cytotoxic drugs are currently in progress to confirm the efficacy of this anti-EGFR agent in the treatment of advanced CRC patients both in the first-line and in the second-line setting.
Cetuximab in combination with bevacizumab
The Bowel Oncology with Cetuximab Antibody (BOND)-2 trial investigated the feasibility and efficacy of bevacizumab added to cetuximab alone or to cetuximab plus irinotecan in patients with irinotecanrefractory disease (Saltz et al., 2005) . In spite of the limitations of this small trial, preliminary data were encouraging, with 23 and 38% RRs, and 6.9-and 8.5-month TTPs, respectively, which appear significantly better than those of historical controls from the BOND-1 trial (RR, 11 and 23%; TTP, 1.5 and 4 months). It should be noted, however, that this is a small trial, with 39 and 35 patients, respectively, reported in the two arms in this preliminary report. Ninety percent of the patients in this study also previously received oxaliplatin, making the combination an effective salvage regimen. No unexpected grade 3-4 toxicities were discovered. A further randomized trial (Cancer and Leukemia Group B [CALGB]/SWOG 80405) will evaluate the role of cetuximab or bevacizumab or both in first-line therapy for CRC. Investigators will choose who initial chemotherapy regimen (modified FOLFOX6 or FOLFIRI) will be used, and patients will then be randomized to receive either cetuximab, bevacizumab or both agents together in conjunction with their chemotherapy. A follow-up study to the BOND-2 study, known as the BOND-2.5 trial, will assess the activity of the cetuximab-bevacizumab-irinotecan combination in patients who have previously progressed through a bevacizumab-containing regimen.
Conclusions and future perspectives
The treatment of patients with metastatic CRC has improved considerably over the last few years with new combination therapies such as irinotecan and/or oxaliplatin plus 5-FU/FA. However, the majority of patients will experience tumor progression. In this setting, there is now evidence that cetuximab treatment is active in patients with EGFR-expressing tumors after failure of both irinotecan-and oxaliplatin-based regimens (Lee and Hoff, 2004) . In particular, the BOND study indicates that patients with metastatic CRC, which are refractory to irinotecan will respond and have a clinical benefit from the combination of cetuximab plus irinotecan. This combination regimen was more active than the cetuximab monotherapy and induced tumor growth control in 56% of the patients with EGFR expression, irrespective of the EGFR expression degree. These results are particularly important considering the high proportion of patients in this study, which were heavily pretreated. Generally, the number of chemotherapeutic lines is a negative predictive factor for efficacy of treatment. However, in the BOND study the efficacy of cetuximab and irinotecan combination was not influenced by the number of previous chemotherapy regimens. Furthermore, these data suggest that cetuximab is able to overcome resistance to irinotecan in patients with CRC. An important question remains to define the patient population who will benefit from cetuximab therapy. The current evidence indicates that high expression of EGFR does not predict a greater response to treatment and that cetuximab appears to be active across the spectrum of EGFR-positive CRC. Furthermore, differently from NSCLC, somatic mutations in the EGFR gene within the tyrosine kinase domain (exons 17-24) do not seem to correlate with cetuximab activity, as suggested by a recent report from the Vogelstein group, which has found only one case of a mutated EGFR gene among tumor specimens from 293 patients with CRC (Barber et al., 2004) . Another point is the correlation between skin rash and efficacy of cetuximab therapy. In five phase II studies, patients who developed acne-like rash survived longer than those who did not develop a rash; those with more intense rash survived even longer. To identify molecular markers correlated with response, a number of study are ongoing. The EVEREST trial is currently ongoing to compare, through both tumor and skin biopsies, the effects of a cetuximab dose-escalation regimen on EGFR and downstream signaling pathway markers with those of the standard cetuximab dose. The next step will be to investigate if cetuximab in association with chemotherapy could be used earlier in the clinical history of CRC, such as in first-line therapy. Promising results have been shown for the association of cetuximab and irinotecan/ 5-FU/FA according to the AIO, the Saltz (IFL) and the FOLFIRI regimens or of cetuximab and oxaliplatin/ 5-FU/FA (FOLFOX-4) in the first-line treatment of advanced CRC as in phase II clinical trials the response rates of this combination were very high (50-80% CR þ PR) with only approximately 10% of the patients progressing during treatment. A further step will be the evaluation of adding the EGFR blockade by cetuximab to the adjuvant chemotherapy in high-risk radically resected CRC patients. However, there are a number of issues that need to be addressed for optimizing cetuximab therapy. Future challenges will lie in the selection of patients who are most likely to respond, in the definition of doses and scheduling, and in defining the combination of cetuximab with other molecular targeted agents, such as oral tyrosine-kinase inhibitors and antiangiogenic drugs.
